All News

Found 534 articles

• Uptake Of Sanofi/Regeneron's Dupixent For Atopic Dermatitis Strong, But Sales Representative Contact Rates Leave Something To Be Desired

  8/22/2017

• Regeneron Heading for Another Hiring Ramp

  8/11/2017

• Regeneron to Terminate Its Antibody Discovery Pact With Sanofi

  8/3/2017

• Sanofi Raises FY 2017 Business EPS Guidance To Broadly Stable At CER

  7/31/2017

• Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi

  7/21/2017

• Sanofi And Regeneron Receive Positive CHMP Opinion For Dupixent (Dupilumab) To Treat Adult Patients With Moderate-To-Severe Atopic Dermatitis

  7/21/2017

• 3 Biotech Stocks That Look Like Apple Did in the 1980s

  6/23/2017

• Sanofi Commits $673 Million in Biologics

  6/14/2017

• 2 Biotechs Insiders Just Bought $70 Million Worth of Stock In

  6/12/2017

• Market Just Got More Crowded as Regeneron, Sanofi's New RA Drug Wins FDA Approval

  5/24/2017

• These 3 Biotechs Could Lead the Next Biotech Boom

  5/24/2017

• 3 Biotechs Bouncing Back After a Tough 2016

  5/23/2017

• Regeneron Reports First Quarter 2017 Financial And Operating Results

  5/4/2017

• Sanofi Delivers Robust Q1 2017 Financial Results

  4/28/2017

• These 3 Big Biotechs Could Have New Blockbuster Drugs Very Soon

  4/10/2017

• Massive $1.2 Billion Biotech Center in New York Will Create Thousands of New Jobs

  4/7/2017

• Sanofi Genzyme Head to Leave After 23 Years on the Job, Replacement Named

  4/6/2017

• This Game-Changing Drug Could Be Regeneron's Next Blockbuster

  3/30/2017

• Sanofi And Regeneron Announce FDA Approval Of Dupixent (Dupilumab), The First Targeted Biologic Therapy For Adults With Moderate-To-Severe Atopic Dermatitis

  3/28/2017

• Regeneron And Sanofi Announce Presentation Of Positive Data From Long-Term Pivotal Phase III CHRONOS Study Of DUPIXENT (Dupilumab) In Moderate-To-Severe Atopic Dermatitis

  3/6/2017